Navigation Links
WuXi PharmaTech Announces Third-Quarter 2011 Results
Date:11/10/2011

SHANGHAI, Nov. 10, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the third quarter of 2011.

Highlights

  • Third-Quarter 2011 Net Revenues Increased 24.0% Year Over Year to $104.0 Million
  • Manufacturing Services Net Revenues Grew 183.8% Year Over Year to $20.1 Million
  • Laboratory Services Net Revenues Grew 9.2% Year Over Year to $83.9 Million
  • China-Based Laboratory Services Net Revenues Increased 10.7% Year Over Year to $63.2 Million
  • GAAP Operating Income Increased 15.8% Year Over Year to $22.2 Million
  • Non-GAAP Operating Income Increased 10.1% Year Over Year to $24.9 Million
  • GAAP Diluted Earnings Per ADS Declined 53.8% Year Over Year to 27 Cents Due to Inclusion in the Prior-Year Results of a Termination Fee Relating to the Proposed Transaction with Charles River Laboratories and an Increase in the Effective Tax Rate
  • Non-GAAP Diluted Earnings Per ADS Increased 2.6% Year Over Year to 31 Cents Due to an Increase in the Effective Tax Rate
  • WuXi Refines Its Full-Year 2011 Guidance
  • Board Member Jeff Leng Elected to Audit Committee

  • Management Comment"WuXi achieved another solid quarter, driven by particularly strong revenue performances in Manufacturing Services, integrated medicinal chemistry, DMPK/ADME, toxicology, formulation, and analytical and bioanalytical services," said Dr. Ge Li, Chairman and Chief Executive Officer. "We exceeded our revenue guidance and met our operating-margin guidance for the quarter. We are on track to achieve full-year 2011 revenues of $402 to $406 million, GAAP operating margin of about 21%, and non-GAAP o
    '/>"/>

    SOURCE WuXi PharmaTech (Cayman) Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related biology technology :

    1. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
    2. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
    3. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
    4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
    5. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
    6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
    7. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
    8. WuXi PharmaTech Announces Third Quarter 2008 Results
    9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
    10. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
    11. Pharmatech 2.0: Introducing Pharmatech Oncology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
    (Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
    (Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
    (Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
    Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
    ... SUNNYVALE, Calif., Sept. 15 Advanced Chemical,Transport, one ... announced the opening of a new location in ... its environmental services -- hazardous,biological and radioactive waste ... and environmental health and,safety outsourcing -- from the ...
    ... China, Sept. 15 3SBio Inc. (Nasdaq:,SSRX), a ... and marketing biopharmaceutical products, today,announced the results of ... of Shareholders held on September 12, 2008 (Friday) ... the Company,s shareholders re-elected Dr. Jing Lou,Liping Xu, ...
    ... CMS, Inc., an Elekta Company and,worldwide leader ... announced the commercial launch of its new 4D ... Focal product line that also includes FocalSim and,FocalPro, ... the,visualization and utilization of 4D image sets to ...
    Cached Biology Technology:Advanced Chemical Transport Opens Merced Facility 2CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM) 2
    (Date:12/19/2014)... Inc., the leading personal genetics company, today announced the publication ... of individuals from across the United States ... hundred years ago, the United States ... continents. This study illuminates how American history and the ongoing ...
    (Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
    (Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
    Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... them into adulthood and may render them more susceptible to ... new UBC study. A team led by UBC researchers ... healthy adults aged 25-40 years. Those who participated in ... circumstances related to income, education and occupation during the first ...
    ... of unicellular marine microorganisms that are not only a crucial ... fossils, which are found in abundance, provide scientists with an ... the history of the earth. Now, planktonic foraminifera ... have given up a secret of their very own. ...
    ... first time, the Society of Interventional Radiology has assembled ... artery embolization, a treatment directed toward a number of ... may occur due to the presence of uterine fibroids. ... "virtual" collection allows health care providers and the public ...
    Cached Biology News:Early-life experience linked to chronic diseases later in life: UBC research 2Surviving mass extinction by leading a double life 2Avoiding hysterectomy: Major interventional radiology E-collection info available 2Avoiding hysterectomy: Major interventional radiology E-collection info available 3
    ... J. Karn (1995) This ... information and methods for the study of ... cycle; reverse transcriptase, ribonuclease H, integrase and ... RNA binding assays; Tat and Rev assays; ...
    Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
    Tachykinin (H-2)...
    Human GATA-2 Affinity Purified Polyclonal Ab...
    Biology Products: